Analyst Ratings For Alnylam Pharmaceuticals (NASDAQ:ALNY)
Today, Alnylam Pharmaceuticals (NASDAQ:ALNY) stock received an upgrade by Goldman Sachs Group, Inc. (The) from Neutral to Buy with a price target of $163.00.
There are 3 sell ratings, 4 hold ratings, 13 buy ratings on the stock.
The current consensus rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) is Buy (Score: 2.50) with a consensus target price of $102.70 per share, a potential 16.03% downside.
Some recent analyst ratings include
- 10/2/2017-Goldman Sachs Group, Inc. (The) Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 9/25/2017-Chardan Capital Reiterated Rating of Buy.
- 9/22/2017-BMO Capital Markets Reiterated Rating of Outperform.
- 9/21/2017-Ladenburg Thalmann Financial Services Reiterated Rating of Buy.
- 9/21/2017-Sanford C. Bernstein Reiterated Rating of Outperform .
- 9/20/2017-Stifel Nicolaus Reiterated Rating of Hold.
Recent Insider Trading Activity For Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY) has insider ownership of 4.30% and institutional ownership of 94.25%.
- On 9/20/2017 Barry E Greene, President, sold 76,815 with an average share price of $100.00 per share and the total transaction amounting to $7,681,500.00. View SEC Filing
- On 5/31/2017 Sanofi, Major Shareholder, bought 297,501 with an average share price of $71.87 per share and the total transaction amounting to $21,381,396.87. View SEC Filing
- On 5/30/2017 Laurie Keating, SVP, bought 11,500 with an average share price of $65.35 per share and the total transaction amounting to $751,525.00. View SEC Filing
- On 5/23/2017 Akshay Vaishnaw, EVP, sold 11,000 with an average share price of $75.00 per share and the total transaction amounting to $825,000.00. View SEC Filing
- On 5/16/2017 Michael Mason, VP, sold 9,375 with an average share price of $70.00 per share and the total transaction amounting to $656,250.00. View SEC Filing
- On 5/15/2017 Akshay Vaishnaw, SVP, sold 43,750 with an average share price of $65.00 per share and the total transaction amounting to $2,843,750.00. View SEC Filing
- On 1/25/2017 Philip A Sharp, Director, sold 15,000 with an average share price of $37.95 per share and the total transaction amounting to $569,250.00. View SEC Filing
Recent Trading Activity for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Shares of Alnylam Pharmaceuticals closed the previous trading session at with shares trading hands.